This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kissei Pharmaceutical Co., Ltd
Drug Names(s): KRP-EPA605
Description: KEA-0447 (KRP-EPA605) is a selective prostaglandin E receptor 1 (EP1) antagonist found to suppress detrusor overactivity in the bladder.
Kissei and KYORIN
In 2009, Kissei and KYORIN reported to have entered into a joint research agreement on the new treatment of overactive bladder.
In 2012, Kissei and Kyorin entered into a joint development agreement in 2012, and with the prospect of initiating a Phase I clinical trial of KEA-0447/KRP-EPA605 for the treatment of overactive bladder.
Partners: Kyorin Pharmaceutical Co., Ltd.
Additional information available to subscribers only: